Renin-angiotensin system and cardiovascular diseases;Das renin-angiotensin-system bei kardiovaskularen erkrankungen

Medizinische Klinik

Volumn 93, Issue 7, 1998, Pages 416-425

  Unterberg, Christina ^a   Kreuzer, Heinrich ^a   Buchwald, Arnd B ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Angiotensin converting enzyme antagonists; Heart failure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; NORADRENALIN; RENIN; VASOPRESSIN;

CARDIOVASCULAR DISEASE; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HEMOSTASIS; HUMAN; LIFE EXPECTANCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0032528213     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03042638     Document Type: Review

References (138)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342 821-8.
2. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10150 individuals. Circulation 1997;95:2358-67.
3. Allen AM, Yamada H, Mendelsohn FA In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart. Int J Cardiol 1990;28 25-33.
4. Ambrosioni E, Borghi C, Magnan B, for the Survival of Mvocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensm-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
5. Anand-Srivastava MB Angiotensin II receptors negatively coupled to adenylate cyclase in rat myocardial sarcolemma: involvement of inhibitory guanine nucleotide regulatory protein. Biochem Pharmacol 1989;38:489-96.
6. Baker KM, Singer HA. Identification and characterization of guinea pig angiotensin II ventricular and atnal receptors: coupling to inositol and phosphate production. Circ Res 1988;62 896-904.
7. Baker KM, Chemin MI, Wixson SK, Aceto JF, Reninangiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990;2593: H324-32.
8. Baker KM, Booz GW, Dostal DE Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Ann Rev Physiol 1992;54 227-41.
9. Bauer P, Regitz-Zagrosek V, Lokies J, Rolfs A, Fleck E. Herabregulation myokardialer AT1 im Endstadium der Herzinsuffizienz geschieht auf mRNA-Ebene. Z Kardiol 1995;84:Suppl 3-9.
10. Bonnardeaux A, Davies E, Jeunamaitre X, et al. Angiotensin II type receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
11. Booz GW, Baker KM. Protein kinase C in angiotensin II signalling in neonatal rat cardiac fibroblasts. Ann NY Acad Sci 1995;752:158-67.
12. Booz GW, Dostal DE, Singer HA, Baker KM. Involvement of protein kinase C and Ca2+ in angiotensin H-induced mitogenesis of cardiac Bbroblasts Am J Physiol 1994;267 C1308-18.
13. Brasch H, Sieroilawski L, Dominiak P Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 1993;22: 699-704.
14. Braunwald E Pathophysiology of heart failure In: Braunwald E, ed. Heart disease Philadelphia: Saunders 1992: 393-419
15. Burgess ML, Carver WE, Terracio L, Wilson SP, Wilson MA, Borg TK. Integrin-mediated collagen gel contraction by cardiac fibroblasts: effects of angiotensin II. Circ Res 1994;74 291-6.
16. Cambien F, Poirier O, Lecerf L, et al, Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction Nature 1992;359 641-4.
17. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol 1996,3:Suppl:S125-31.
18. Chein KR, Knowlton KU, Zbu H, Chein S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiological response. FASEB J 1991;5:3037-46.
19. Chinese Cardiac Study Collaborative Group. Oral captopril versus plazebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-I) Lancet 1995;345:686-7.
20. Chiu AT, Mc Call DE, Nguyen TT, et al. Discrimination of angiotensin II receptor subtypes of dithiotreitol Eur J Pharmacol 1989;170:117-8
21. Cohn JN, Archibald DG, Ziesche S. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engi J Med 1986;314:1547-52.
22. Cohn JN, Johnson G, Ziesche S. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N EnglJ Med 1991;325:303-10
23. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316 1429-35.
24. Dawson S, Henney A. The status of PAI-1 as a risk factor for artenal and thrombotic disease. Atherosclerosis 1992;95:105-17.
25. De Mello WC, Crespo MJ Cardiac refractoriness in rats is reduced by angiotensin II. J Cardiovas Pharmacol 1995;25 51-6.
26. Do Y-S, Shinagawa T, Tam H, Inagami T, Hseuh W. Characterization of pure human renal renin evidence for a suburut structure. J Biol Chern 1987;262:1037-43.
27. Drexler H, Havoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1569-601.
28. Dzau VJ, Ellison KE, Brody T, Ingelfinger JR, Pratt R A comparative study of the distribution of renin and angiotensinogen messenger nbonucleic acids in rat and mouse tissues Endocrinology 1987; 120 2334-8.
29. Elton TS, Stephan CC, Taylor GR, et al. Isolation of two distinct type I angiorensin II receptor genes. Biochem Biophys Res Comm 1992:184-1067-73.
30. Farber HW, Center DM, Rounds S, Danilov SM Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothehal cells Eur Heart J 1990; 11:100-7.
31. Farhy RD, Ho KL, Carrerero OA. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992;182:283-8
32. Freeman EJ, Tallant EA. Vascular smooth muscle cells contain ATI angiotensin receptors coupled to phospholipase D activation. J Biochem 1994;304:543-8.
33. Garg UC, Hassid A. Nitrid oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cGMP-independent mechanism. Biochem Biophys Res Commun 1990;171:474-9.
34. Gilbert EM, Sandoval A, Carrabee P, Reselund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases *-receptor density in the failing human heart. Circulation 1993;88:472-80.
35. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability oflosartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. J Hypertension 1995;13-S77-80
36. Gottlieb SS, Dickstem K, Fleck E, et al. Hemodynamic and neurohumeral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-10.
37. Gnendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle J Cardiovasc Pharmacol 1989;14:Suppl 6:S27-33.
38. Gruppo Italiano per lo Studio della opravivenza nell Infarto miocardico. GISSI-3. Effects of lisinopril and transdennal glyceryl tnnitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:115-22.
39. Hahn AWA, Resink TJ, Bemhardt J, Ferracin F, Buhler FR. Stimulation of autocrine platelet-derived growth fector AA-homodimer and transforming growth factor * in vascular smooth muscle cells. Biochem Biophys Res Comm 1991;178:1451-8.
40. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen avtivator inhibitor-1 expression in the neomtima ofballoon-injured rat aorta. Circulation 1996,93:1073-8.
41. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ, Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82
42. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, et al Angiotensin I and II exert motropic effect in atrial but not in ventricular human myocardium. Circulation 1993;88:1228-37.
43. Holycross BJ, Peach MJ, Owens GK. Angiotenstn II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro. J Vasc Res 1993;30:80-6
44. Horiuchi M, Koike G, Yamada T, Mukoyama M, Nakajima M, Dzau VJ. The growth-dependent of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and -2. J Biol Chem 1995;270:20225-30.
45. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
46. Itnai T, Miyazaki H, Hirose S, et al Cloning and sequence analysis of cDN A for human renin precursor. Proc Natl Acad Sci USA 1983;80;7405-9.
47. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995,345.669-85.
48. Israth ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology Ann Intern Med 1992;117:234-42
49. Jonston CI. Angiotensin receptor antagonists: focus on losartan, Lancet 1995;346:1403-7.
50. Kawahara Y, Sunako M, Tsuda T, Fukuzaki M, Fukumoro Y, Takai Y, Angiotensin II induces expression of c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Comm 1988;150:52-9
51. Keidar S, Brock JG, Aviram M Angioterisin II enhanced lipid peroxibation of low-density lipoprotein Am Physiol Soc 1993;8:245-8.
52. Kevins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothehal cells is mediated by the hexapeptide angiotensin IV.J Clin Invest 1995;96:2515-20.
53. Klinger G, Jaramillo N, Ikram H. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 1997;29: Suppl A:205A.abstract.
54. Knape JTA, van Zwieten PA. Positive chronotropic activity of angtotensin II in the pithed normotensive rat is primarily due to activation of cardiac β1-adrenoceptors Naunyn-Schmiedeberg's Arch Pharmacol 1988;338:185-90.
55. Kobayashi M, Furukawa Y, Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog hearts. EurJ Phamacol 1978;50:17-25.
56. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin U receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204-11.
57. Kokkonen JO, Saannen J, Kovanen PT. Regulation oflocal angiotensin II formation in the human heart in the presence of interstitial fluid Circulation 1997;95:1455-63.
58. Lacourciere Y, Brunner H, Irwin R, et al. and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosteron system on cough. J Hypertens 1994;12:1387-93
59. Lam JYT, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries Circulation 1992;85:1542-7.
60. La Rouvere MT, Mortara A, Pantaleo P, Maestri R, Cobelli F, Tavazzi L Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90:838-43
61. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WB. Prognostic implications of echocardiographically determined left ventricular mass, in the Framingham heart study N Engt J Med 1990;322:1561-6.
62. Lièvre M, Guéret P, Gayet C, et al. on behalf of the HYCAR Study Group Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995,25:92-7.
63. Lindpamtner K, Jin M, Niedermeyer N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused bearing heart. Circ Res 1990; 67:564-73.
64. Lindpaintner K, Lu W, Niedermeyer N, et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol 1993,25:133-43.
65. Lindpamtner K, Lee M, Larson MG, et al. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass N Engl J Med 1996;334:1023-8.
66. Lokuta AJ, CooperC, Gaa ST, Wang HE, Roger TB Angiotensin II stimulates the release of phosphohpid-denved second messengers through multiple receptor subtypes in heart cells J Biol Chem 1994;269:4832-8
67. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection Circulation 1994;90:2056-69.
68. Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M. Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J Clin Invest 1994;93:1592-601
69. Mc Donald KM, Mock J, Dáloia A, et al. Bradykmin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8.
70. MERCATOR Study Group The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis Study Group. Does the new angiotensin-converting-enzyme inhibitor cilazapril prevent restenosis after transluminal coronary angioplasty? Results of the MERCATOR Study: A multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992;86:100-10.
71. Moss A, Hall W, Cannom DS, et al for the Multicenter Automatic Defibrillator Implantation Tnal Investigators Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia N Engl J Med 1996;335:1933-40
72. Mukoyawa M, Nakajima M, Honuchi M, Sasamura H, Pratt RE, Dzau VJ, Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors J Biol Chem 1993;268;24539-42.
73. Munzenmaier DH, Grenne AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996;27:760-5.
74. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-6.
75. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-24.
76. Naftilan AJ, Gilhland GK, Eldridge CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II, Mol Cell Biol 1990;10:5536-40.
77. Nagano M, Higaki J, Nakamura F, et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 1992;19:708-12.
78. Nakai K, Itoh C, Miura HKY, et al. Deletion polymorphisnm of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese Circulation 1994;90:2199-202.
79. Nakajima M, Huchtinson HG, Fujinaga M. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92 10663-7.
80. Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril Am J Cardiol 1984;53:1044-9
81. Neuß M, Regitz-Zagrosek V, Fleck E. Human cardiac fibroblasts express an angiotensin receptor with unusual bmding characteristics. Biochem Biophys Res Commun 1994;204:1334-9.
82. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977;196:441-44.
83. Osterziel KJ, Rohrig N, Dietz R, Manthey J, Hecht J, Kübler W. Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. Eur Heart J 1988;9:1137-45.
84. Osterziel KJ, Hänlein D, Wilenbrock R, Eichborn C, Luft FC. Dietz R Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br Heart J 1995;73:517-22.
85. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infercted left ventricle of the rat. Circ Res 1985;57:84-95.
86. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction experimental observations and clinical implications. Circulation 1990;81:1161-72.
87. Pfeffer MA, Braunwald E, Mové LA, et al. on behalf of the SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
88. Pitt B, Chang P, Grossman W, Dunlay M, Timmermans PB. Rationale, background, and design of the randomized receptor antagonist-angiotensin-converting enzyme inhibitor study (RAAS). AmJ Cardiol 1996;15:1129-31.
89. Pitt B, Segal R, Martinez FA, et al. on behalf of ELITE Study Investigators Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997;349:747-52.
90. Radomski MW, Palmer RMJ, Moncada S. The antiaggreganng properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92 639-46
91. Rakugi H, Jacob HJ, Kneger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima Circulation 1993;87:283-90.
92. Raynolds MV, Bnstow MR, Bush EW, et al. Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet 1993;342:1073-5.
93. Regitz-Zagrosek V, Fnedel N, Bauer HP, et al. Regulation, chamber lo calization, and subtype distribution of angiotensin II receptors in human hearts Circulation 1995;91:1461-71
94. Regitz-Zagrosek V, Neuß M, Warnecke C, Holzmeister J, Hildebrand AG, Fleck E. Angiotensinrezeptoren - Organ- und subtypspezifische Regulation bei kardiovas-kulären Erkrankungen und durch Modulation des Renin-Angiotensin-Systems Z Kardiol 1995;84:Suppl 4.61-9.
95. Regitz-Zagrosek V, Neuß M, Holzmeister J, Warnecke C, Fleck E. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. J Mol Med 1996;74:233-51.
96. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE, Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II - evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-73.
97. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
98. Rochette L, Ribout C, Belichard P, Bril A, Devissaguet M. Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and penndopril on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion in rat. Clin Exp Hypertens 1987;A9: 365-8.
99. Rolfs A, Weber-Rolfe I, Regitz-Zagrosek V, Kallisch H, Riedel K, Fleck E. Genetic polymorphisms of the angjotensin II type 1 (AT1) receptor gene. Eur Heart J 1994;15:Suppl D:108-12.
100. Sadoshima J, Xu Y, Slayter S, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-84.
101. Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine and renal angiotensin II type-1 receptor Nature 1991;351: 230-2
102. Sawa H, Tokuchi F, Mochizuki N, et al. Expression of the angiotensinogen gene and localization of its protein in the human heart. Circulation 1992;86:138-46.
103. Schiffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type- 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;5 2273-81.
104. Schorb W, Booz G, Dostal D, Conrad K, Chang K, Baker K. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993;72:1245-54.
105. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein C, Lorell B, Increased rat cardiac angiotensin-converting enzyme activity and mRNA levels in pressure overloaded left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J Clin Invest 1990;86-1913-20.
106. Schunkert H, Hense H-W, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy N Engl J Med 1994;330:1634-8
107. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in the rat kidney and heart using the non-peptide antagonist DuP 753 and PD 123177. J Hypertens 1991;9:Supll6:S224-5.
108. Sen S, Tarazi RC, Bumpus FM. Effect of converting enzyme inhibitor (SQ 14225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980; 2:169-76.
109. Sharpe N, Smith H, Murphy J, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;1 255-9.
110. Skidgel RA, Englebrecht S, Johnston AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984;5: 769-76
111. Skidgel RA, Erdös EG. Novel activity of human angiotensin I converting enzyme release of the NH2- and COOH-terminal tnpeptides from the luteinizng hormone-release hormone. Proc Natl Acad Sci USA 1985;82:1025-9.
112. Smith D, Gilbert M, Owen WG. Tissue plasrninogen activator release in response to vasoactive agents. Blood 1985;66:835-9
113. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325 293-302.
114. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left: ventricular ejection fractions N Engl J Med 1992;327:685-91.
115. Soubrier F, Alhenc-Gelas F, Hubert C, et al. Two pucative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 1988;84:9386-90.
116. Stafford RS, Saglam D, Blumenthal D. Low rates of angiotensin-converting enzyme inhibitor use in congestive heart failure. Circulation 1996;94:I-194. abstract.
117. Stoll M, Steckelings UM, Paul M, et al. Theangiotensin AT 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95: 651-7.
118. Stouffer GA, Og K. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res 1992;70: 820-8
119. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994;94:304-10.
120. Studer R, Sütsch G, Müller B, Oechslin E, Hess OM, Drexler H. Role of pressure-overload and wall stress for cardiac gene expression of angiotensin I converting enzyme in humans Circulation 1994;90:pt 2;I-451.abstract.
121. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, on behalf of the Consensus II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327;678-84.
122. Takayanagi R, OhnakaK, Sahai Y, et al. Molecular cloning, sequence analysis and expression of a c-DNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 1992;183:910-5.
123. Tarazi RC, Fouad FM, Ceimo JK, Bravo EL. Renin, aldosterone and cardiac decompensation: Studies with an oral converting enzyme inhibitor in heart failure. Am J Cardiol 1979;44:1013-8.
124. Tewksbury DA. Angiotensinogen. Fed Proc 1983;42: 2724-8.
125. Tikkanen I, Omvik P, Jensen HA Comparison of the angiotensin II antagonist Iosartan with the angiotensin enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995;13:1343-51.
126. Timinerinans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
127. Tiret L, Bonnardeaux A, Poiner O, et al Synergistic effects of angiotensin-converting enzyme and angiotesnin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-3.
128. Owens GK Mechanisms of angiotensin - and arginine vasopressin - induced increases in protein synthesis and content in cultured rat aortic smooth muscle cells. Circ Res 1991;68 288-99.
129. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts Circ Res 1990;66:883-90.
130. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-57.
131. Urata H, Nishimura H, Ganten D Mechanisms of angiotensin II formation in humans Eur Heart J 1995;16 79-85.
132. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells. J Clin Invest 1995;95: 955-1001
133. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium Fibrosis and renin-angiotensin-al-dosterone system. Circulation 1991;83:1849-65.
134. Weber H, Taylor DS, Molloy CJ Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. J Clin Invest 1994;93:788-98.
135. Wong PC, Hart SD, Zaspel A, Chiu AT, Smith RD, Timmermans PBMWM, Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (All-1) and PD 123177 (AII-2). J Pharmacol Exp Ther 1990;255:584-92.
136. Yamada T, Honuchi M, Dzau VJ. Mitogen-activated protein (MAP) kinase dephosphorylation by angiotensin II type 2 receptor induces apoptosis Circulation 1995;92:Suppl:I-499.abstract.
137. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxy-peptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta 1970;214:374-6.
138. YusufS, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-78.